|
|
CaPNP (CaPtivant)(TM) |
|
Vaxjo ID |
126 |
|
Vaccine Adjuvant Name |
CaPNP (CaPtivant)(TM) |
|
Adjuvant VO ID |
VO_0005295
|
|
Description |
mineral salt that induces Th1/Th2 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Captivate Pharma (Pennsylvania) |
|
Host Species for Testing |
Mouse |
|
Components |
Calcium phosphate nanoparticles (CaPNPs) |
|
Preparation |
The components of a formulation of 12.5 mM calcium chloride, 12.5 mM dibasic sodium phosphate, and 15.6 mM sodium citrate were mixed together and stirred for 48 h |
|
Function |
Type: mineral salt vaccine adjuvant. Induces Th1/Th2 mixed immune profile. Antigen carrier; Innate immune enhancer/activator, stimulates the immune response by inducing effective mucosal immunity. |
| References |
(Morcol, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=11]
Morcol et al., 2019: Morcol T, Nagappan P, Bell SJD, Cawthon AG. Influenza A(H5N1) Virus Subunit Vaccine Administered with CaPNP Adjuvant Induce High Virus Neutralization Antibody Titers in Mice. AAPS PharmSciTech. 2019; 20(8); 315. [PubMed: 31591662].
Yang et al., 2021: Yang J, Yue L, Yang Z, Miao Y, Ouyang R, Hu Y. Metal-Based Nanomaterials: Work as Drugs and Carriers against Viral Infections. Nanomaterials (Basel, Switzerland). 2021; 11(8); . [PubMed: 34443959].
|
|
